Anti-CD3 Treatments Move to Phase III Trials

Anti-CD3 treatments have moved into Phase III clinical trials and show promise to delay the progression of diabetes in the newly diagnosed. These achievements demonstrate the success of JDRF’s strategy to fill gaps in the drug development pipeline, by initially funding proof-of-concept clinical trials and then helping small companies move discovery research through early clinical testing until bigger companies step in and fund the large trials needed for FDA approval.